Boehringer's anti-clotting drug Pradaxa gains EU approval

08/4/2011 | Reuters

The European Commission approved Boehringer Ingelheim's Pradaxa for preventing stroke in people with atrial fibrillation. The approval underscores Boehringer's lead over other drugmakers in replacing anticoagulant warfarin.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA